RxDoctor Payments Data

Jennifer Loop-Miller

Psychiatric/Mental Health · South Bend, INNPI 1730698267

Payments from drug & device makers

$2,308in general payments, 2019–2025

Across 49 payments — averaging $47.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$553
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$552
  • Neurocrine Biosciences, Inc.$400
  • AbbVie$222
  • Axsome Therapeutics, Inc.$144
  • Livanova USA, Inc.$127
  • plus $310 from 11 others

What the payments were for

  • Food & beverage$2,19095%
  • Education$1185%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,308 in reported general payments places this provider in the 75th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$29,414
Medicare patients
80
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate22$161,247
VraylarCariprazine Hcl73$118,829
RexultiBrexpiprazole15$34,305
LybalviOlanzapine/Samidorphan Malate18$31,375
CaplytaLumateperone Tosylate13$24,071
ClozarilClozapine18$12,124
Clozapine109$10,397
VyvanseLisdexamfetamine Dimesylate23$8,810
Fluvoxamine Maleate ErFluvoxamine Maleate14$8,800
Paliperidone ErPaliperidone16$8,720
Methylphenidate ErMethylphenidate Hcl18$7,643
Aripiprazole107$6,278
Olanzapine145$5,251
Divalproex Sodium ErDivalproex Sodium78$4,830
Lamotrigine OdtLamotrigine17$4,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$400$161,24722 claims
AbbVieVraylar$222$118,82973 claims
Otsuka America Pharmaceutical, Inc.Rexulti$553$34,30515 claims
Alkermes, Inc.Lybalvi$14$31,37518 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$552$24,07113 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$26$8,81023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →